SeaStar Medical Holding Corporation (ICU) Earnings Call Transcript
March 25, 2026
Earnings Call Speaker Segments
Thanks, Josh. Good afternoon, and I appreciate everyone being on this call for SeaStar Medical's discussion of financial results for the fourth quarter and the full year 2025. This is Jackie Cossmon, and I'm with Wheelhouse Life Science Advisors. With me today from SeaStar Medical are Eric Schlorff, our Chief Executive Officer; Dr. Kevin Chung, Chief Medical Officer; Tim Varacek, Senior Vice President of Commercial and Business Operations; and Mike Messinger, Chief Financial Officer. Listeners should be aware that management's remarks on this call will contain forward-looking statements as defined under the federal securities laws; such forward-looking statements carry risks and uncertainties that might cause actual results to differ materially from any results that are anticipated. To see a list and description of those risks and uncertainties, please review SeaStar Medical's filings with the Securities and Exchange Commission. In addition, what is said on this conference call includes information that is accurate only as of the date of the live broadcast, March 25, 2026. Except as required by law, SeaStar Medical assumes no obligation to revise or update any statements to reflect events or circumstances. I'd now like to hand the call over to Eric. Eric?
Absolutely. Thanks, Jackie, and I appreciate everyone being here with us today. We're thrilled to walk you through what we accomplished during the last year, along with our plans going forward and the enthusiasm we bring to our work at SeaStar Medical. During 2025 and continuing into the opening quarter of this year, we broadened utilization of QUELIMMUNE therapy for ultra-rare pediatric AKI. We brought on 13 additional customers from highly ranked children's hospitals, which lifted our total customer count to 16 while also deepening order volumes across that base. For 2025, we recorded net revenue exceeding $1 million from QUELIMMUNE sales, accompanied by gross profit margins above 90% that resemble those seen in pharmaceuticals. Beyond that, we moved forward on developing the SCD therapy as a possible option for adult AKI patients in the ICU who are undergoing continuous renal replacement therapy, reaching more than 50% enrollment — 181 of 339 patients have been enrolled so far in the NEUTRALIZE-AKI pivotal trial. We likewise kicked off a modular premarket application, or PMA, submission process for the SCD therapy as a potential adult AKI treatment; the FDA has already given us Breakthrough Device Designation for that indication, and we hope this modular PMA submission may help accelerate the PMA approval pathway. And notably, we kept solid discipline over costs and significantly strengthened the company's balance sheet by bringing in roughly $24 million of capital across 2025, along with cutting operating liabilities by more than $3 million. Now let's shift to 2026. We've established 4 key milestones aimed at creating stakeholder value and putting us on firm footing for 2027 and afterward. Our top objective for this year — and a big source of future revenue potential — is pushing the SCD therapy ahead for the adult AKI indication. We intend to wrap up enrollment in the NEUTRALIZE-AKI pivotal trial near the close of 2026. Should that trial succeed, we'd be positioned to complete our PMA submission in the following year. Given a market opportunity 50x larger than the pediatric AKI market, we're extremely enthusiastic about what lies ahead. When it comes to QUELIMMUNE, we aim to grow our customer base further during 2026. Momentum in the pediatric market remains strong, thanks to publication of our SAVE Registry data in Pediatric Nephrology and powerful endorsements from current customers. Our plan is to bring on 15 additional top-ranked children's medical centers this year, targeting $2 million in net profit — product revenue from QUELIMMUNE sales in 2026, which would mark a substantial jump over 2025. We'll also assess how broadly the SCD therapy might apply in a new indication for which we've received the Breakthrough Device Designation approval pathway through the FDA. Late in 2025, we announced the start of a clinical trial testing the SCD therapy in patients who have acute congestive heart failure with cardiorenal syndrome and are awaiting left ventricular assist device implantation. That trial is investigator-led and receives funding from the NIH. This is a space where the need is dire, and our hope is to deliver a remedy for those individuals whose chances of living are minimal, since hyperinflammation has left them too weakened to be able to have the operation that would make their state better. Last of all, we will collaborate with the FDA to secure faster clearance for the indications in our pipeline. Through the Humanitarian Use and Breakthrough Device Designations, there is potential for us to give patients earlier access when they suffer from damaging hyperinflammatory conditions that mean irreversible organ failure or death. To put it briefly, the coming year is one we are enthusiastic about, and we anticipate sharing updates on how we are doing. At this point, I will hand things over to Tim so he can talk about what we have achieved commercially and where the market opportunities lie. Tim?
Appreciate it, Eric, and thank you all for being here today. I'm happy to share that we closed out the year carrying significant momentum, and that same momentum is carrying over as we move through the first quarter of this year. Since the fourth quarter got underway, we've brought on 6 more customers. And what's especially notable is that order volumes from a large number of our customers are climbing considerably. QUELIMMUNE net revenue came in at $315,000 for the fourth quarter, and net revenue for the first quarter has already surpassed that figure; to frame that properly, we've said from the start that this market is ultra-rare. This market matters to us, both because we think we're saving lives and because it offers strong validation of our SCD technology, and on top of that, it opens the door to potential future opportunities in the adult market. As adoption of the QUELIMMUNE therapy keeps expanding, key opinion leaders in this field are now putting out publications and reports on how QUELIMMUNE is being used. Back in February, we shared that 9 pediatric AKI experts were co-authors on the publication of the SAVE Registry data in the peer-reviewed journal, Pediatric Nephrology. Beyond that, later this month we'll be sponsoring and hosting an educational symposium at the AKI CRRT meeting in San Diego. I've talked before about our plans to build the QUELIMMUNE brand in pediatric AKI, and this symposium illustrates one of the new resources we're putting together, an advanced practice provider advisory board; this collection of patient care level and operational experts will take part in a panel discussion focused squarely on the QUELIMMUNE adoption process, giving aspiring institutions best practices and helping them cut down the overall time line to QUELIMMUNE activation. A large list of attendees is already signed up for this event, which will include discussions about the use of QUELIMMUNE led by a number of prominent key opinion leaders who were early adopters of the QUELIMMUNE therapy. In addition, an abstract from Dr. James Odom at the University of Alabama, Birmingham Children's Hospital has been accepted for presentation. It will share findings regarding the anti-inflammatory properties of our SCD therapy; in brief, we're witnessing strong growth in QUELIMMUNE orders, with the pediatric AKI field now regarding it as a key therapy for renal replacement therapy patients in the ICU, and one highly regarded institution has formally adopted QUELIMMUNE as its standard of care. Now let's turn to 2026. We hold great expectations for helping patients by getting QUELIMMUNE therapy to additional pediatric hospital systems. We are relentlessly focused on bringing on new sites as quickly as we can; and the more sites we bring on, the more we reduce our revenue variability and ultimately create a predictable and reliable stream for our investors and SeaStar Medical. That has always been our goal. The pediatric AKI market is small yet important, and we believe it represents a total market of roughly $100 million, and we've refined our target market population to pediatric patients in the top 50 children's hospitals in the U.S. We think it's possible for us to take a meaningful piece of this market and generate substantial value for our stockholders, while also bringing in important revenue for SeaStar Medical. And in our view, this is just the start of the commercial possibilities for our SCD therapy; so with that, I'll hand the presentation over to Kevin Chung, our Chief Medical Officer, who is going to talk about where our NEUTRALIZE-AKI effort stands so far. Kevin?
Thanks, Tim, and I appreciate everyone who's with us on the call today. Our team is putting in serious effort to finish enrolling patients in NEUTRALIZE-AKI, our pivotal study. Starting in Q4, we brought on 4 more clinical sites and signed up an additional 55 patients, which lifts the cumulative number of enrollees to 181 out of the 339 we're aiming for. For anyone who's newer to the story, NEUTRALIZE-AKI is a randomized controlled trial meant to determine if as many as 10 sequential 24-hour SCD treatments can enhance 90-day survival or renal recovery among critically ill individuals suffering acute kidney injury who need continuous renal replacement therapy, also known as CRRT. Mortality or dialysis dependence at 90 days, taken together, forms the primary endpoint. Our goal is to wrap up enrollment near the end of the year, which sets us up to possibly share top line results during mid-2027; we're pushing hard to grow our clinical footprint, adding high-volume sites in the coming quarter to build enrollment momentum. At the same time, we're proactively getting ready those parts of the premarket approval that don't hinge on clinical outcomes, consistent with FDA guidance, to help make the review process more efficient. After we've completed and evaluated the NEUTRALIZE-AKI trial, if the results show the therapy works and is safe, we intend to move quickly and submit the remaining PMA modules under our Breakthrough Device Designation, which might allow us to qualify for a faster FDA review. The pediatric AKI indication was obtained through a Humanitarian Device exemption route, which requires IRB approval at each site before the product can be used and, in our case, entailed the mandatory SAVE Registry to monitor post-market safety for QUELIMMUNE. By comparison, should SCD therapy gain approval for adult AKI, we would be able to market it as a therapeutic device without those IRB-related hurdles, which would make hospital adoption much easier and allow commercial growth to move more quickly. Turning to the SAVE Registry, which tracks how QUELIMMUNE is used commercially in critically ill kids: we said earlier this month that 50 patients have now been enrolled there. The FDA had originally asked for 300 patients, but after looking at data from the registry's first 21 patients, the agency lowered that requirement, and 50 is the new figure. We still need 28-day safety data from the most recently enrolled patients, and we'll soon send the FDA a report covering the top line safety data. Before we move on, I want to highlight a paper that came out recently in Pediatric Nephrology. It covers the initial real-world use of QUELIMMUNE after approval, based on data from the first 21 patients who joined the SAVE Registry. Well-known specialists served as co-authors, and it was a pleasure to see the piece published in such a prestigious peer-reviewed journal. Within that first group of pediatric patients who had AKI along with sepsis and needed renal replacement therapy, there were zero device-related adverse events, no infections, and no signs of immunosuppression. The survival figures are promising—76% at both day 28 and day 60, and 71% at day 90—which points to an approximately 50% drop in mortality compared with historical controls, consistent with the results from our earlier registration study. The safety profile for QUELIMMUNE looks stronger thanks to these initial real-world results, and they point to its ability to substantially better outcomes for a very fragile group of children. Ultimately, what matters here is offering seriously ill kids, who would have no alternatives otherwise, an actual shot at living. On top of that, expanding the pipeline of SCD indications remains a major priority for us during this year. In 2025 we launched the NEUTRALIZE-CRS clinical trial, and we're currently enrolling people suffering from chronic heart failure along with cardiorenal syndrome; roughly 20 patients who can't receive an LVAD or a heart transplant are expected to join this ICU-based study. What's significant is that this trial introduces a differentiated treatment approach. In NEUTRALIZE-CRS, treatment is given on an intermittent basis rather than continuously as in NEUTRALIZE-AKI — as much as six hours per day, for as many as six days. The goal of this design is to demonstrate that intermittent SCD therapy is feasible, and that it could potentially be delivered in outpatient settings while reaching a wider set of chronic hyperinflammatory conditions. Taking a step back, this study is part of our broader plan to grow SCD therapy across several indications. In AKI, in CRS, or in other areas, our platform, we believe, could deliver meaningful improvements in outcomes for patients dealing with hyperinflammation. I'll now turn things over to Mike Messinger, our CFO. Mike?
Appreciate that, Kevin, and we're glad to have everyone joining this call. What I'll do is walk you through a brief summary of our financial results for both Q4 and the entire year that wrapped up on December 31, 2025. One thing to flag: within roughly the next day, our Form 10-K will be filed with the SEC, and inside it you'll find a fuller discussion of how the company performed financially across the 3-month and 12-month periods ending December 31, 2025. You can access that Form 10-K on sec.gov, or alternatively at seastarmedical.com. Turning to the numbers, net revenue generated by QUELIMMUNE sales totaled approximately $315,000 in Q4 of 2025, compared with $67,000 during the same quarter of 2024. Tim mentioned this earlier, and it's true — during the first quarter of 2026, our sales have already gone past what we did in the fourth quarter. On top of that, this quarter brought in $105,000 in net revenue from the sale of the SCD to the AREVA Research Institute. That order is the first of 2 that the institute has placed. You might recall that we first discussed this relationship in June of 2025. Funding for the AREVA Research Institute's program comes from a Department of Defense grant, which backs their pioneering work on extracorporeal immunomodulation aimed at lowering inflammation following severe burns, inhalation injury and septicemia. Under the DoD grant, funds are allocated for buying the SCD from SeaStar Medical so AREVA can utilize it in their research; an additional order valued at as much as $100,000 is anticipated by us. The timing of that order's arrival remains unclear, though we'll record the revenue as it is earned across upcoming quarters. QUELIMMUNE net revenue for the full year that ended December 31, 2025 came in at $1.1 million, which compares with $135,000 in QUELIMMUNE net revenue during 2024. This gain mirrors the fact that we had our first complete year of selling the product, whereas 2024 included just half a year. Yet what mattered even more in fueling that rise was growth in our purchaser roster, made up of the nation's leading children's hospitals. Turning now to gross profit. Looking at the statement of operations for both the fourth quarter and the entire year, you'll see that our gross profit margin came in above 90%. Just to remind everyone, before 2025 we weren't recording any cost of goods sold, because the QUELIMMUNE units we sold had already been expensed to R&D before the product received approval and entered commercialization — that approach aligns with U.S. GAAP. On the operating expense side, Q4 of 2025 saw those costs drop to $3.4 million, down from $4.8 million during the same quarter in 2024. Across the full year, we reduced operating expenses to $13.4 million, which compares with $18 million the year before. We made these cuts on purpose. They show that we keep exercising restraint, and that we can draw on the wide-ranging expertise, skill, and drive of our people, coordinating throughout the company to secure its success. For the fourth quarter of 2025, our net loss came to roughly $2.9 million, which works out to $0.80 per share, calculated using weighted average shares outstanding of about 3.6 million. In the fourth quarter of 2024, by contrast, the net loss was around $4.4 million, or $8.98 per share, with weighted average shares outstanding of approximately 492,000. When you look at the entire year for 2025 and for 2024, our net loss came in at $12.2 million and $24.8 million, respectively — which again speaks to both QUELIMMUNE being adopted more widely and the strong discipline we showed in managing and bringing down our expenses. Now moving to our financial position: we keep making substantial improvements to the company's balance sheet, helped by adding roughly $23.9 million in capital over the course of 2025 and cutting $3.1 million in operating liabilities, and we carry no long-term debt. As of December 31, 2025, cash on our balance sheet sits at approximately $12 million, which compares to $1.8 million as of December 31, 2024. With that, Eric, I'll hand it back to you.
Appreciate that, Mike. What we laid out for you today is going to drive us toward hitting our 2026 milestones. Our intentions are to keep growing the uptake of QUELIMMUNE, push forward with getting patients enrolled in the NEUTRALIZE-AKI pivotal study, and widen the label as well as speed up possible clearances for the indications tied to our SCD therapy. In our view, what's coming down the road for SeaStar represents a sizable opportunity, and we're eager to share updates on how things develop. So with that said, I'll hand it over to the operator to begin the Q&A portion. Operator?
Thanks for the update today. My first question concerns QUELIMMUNE adoption and the additional centers. You mention aiming at roughly 15 more pediatric centers where you'd like to launch QUELIMMUNE. What makes you confident you can reach that figure during this year?
Yes. Thank you, David. This is Eric. We appreciate you being with us today. Tim, would you like to take that one?
Of course. Thank you for asking that, and I believe we've gotten off to a fairly fast start. In Q1, we've already brought on 6 sites in pursuit of that objective. And it's worth noting that site additions represent an ongoing effort rather than a one-time event, and it does require patience. We therefore maintain a highly structured roster of hospitals. Among those top 50, we've been engaging with a large number of them, guiding each through the adoption journey, which does take a while. That said, at this stage we can project ahead roughly when those sites should be in a position to go live and turn into QUELIMMUNE customers. Beyond that, we're approaching the moment with the SAVE Registry where we think the criteria for that registry have been satisfied. We'll collaborate with the FDA to examine the data coming out of that registry, and what we're aiming for is making this registry something sites opt into rather than something they must do from here on. Should that come to pass, we'd in theory be able to advance sites more rapidly through the steps, since a substantial portion of this timeline has involved standing that registry up and getting it operational. So our confidence is high regarding the new sites we're adding. Our confidence is high regarding the projection. And overall, our confidence is high about the momentum we're building with QUELIMMUNE in the pediatric community.
All right, that's great, thank you for that. I'd like to ask whether you can share some thoughts regarding the production capacity for the SCD. I'm not sure whether that's a concern at this point given the pediatric indication; however, when you look forward toward the adult indication and securing approval for it, will any kind of investment be required so you can satisfy the potential commercial demand?
Yeah. David, I appreciate it once more. That's an excellent question. We actually have a lot of confidence in the supply chain for the SCD, covering both pediatrics and adults. As we've told the market, Fresenius Medical serves as our contract manufacturer, and they clearly possess deep expertise and the capacity needed to manufacture sufficient SCDs for pediatrics as well as adults.
All right, that sounds good. Then, just briefly regarding the CRS study, I'm not sure whether you have any sense of what the timelines look like for that trial in terms of enrollment. And then, perhaps even more significantly, assuming the study turns out positive, what would the next steps be for that indication?
Yes, I'll take that question. We haven't actually provided any guidance regarding when that study might be finished. What we announced during the past year is that we got one site started, and it's now activated. We intend to keep activating sites until we reach 5 in total. Beyond that, I know the teams are actively screening patients as well. So we'll simply update the market as the year moves forward. Ultimately, if the study succeeds, we think that given the orphan nature of the small patient population for this CRS bridging to LVAD patient population, it would actually qualify for Humanitarian Device exemption — the same designation we hold for the pediatric one — which truly lets us get the therapy to these much-needed patients who really have no other solution, yet it doesn't require us to run a large clinical study the way we are for the adult AKI indication.
All right, that sounds fine. Then for the final item, a question about finances; I believe this one is directed at Mike. What's the right way to think about our expenditures for this year? Would you say it will resemble the prior year, 2025, more closely, or 2024 instead?
Yes. Go on, Mike.
Absolutely. Thank you, and I appreciate you being here, David. We really do value that. What we're observing is that spending is tracking much closer to 2025 levels, and roughly consistent with what we saw during the prior quarter or thereabouts. The positive aspect is that our team is now ready to carry out this plan, on the commercial side as well as the clinical side; so feel free to factor that in as you think about how the run rate will develop.
Anthony, I had a question. Kevin, I believe you mentioned that 181 of the 339 target patients have either been treated or enrolled. Of those 181, how many have actually completed treatment by now, assuming not every one of them has? And what insights have you gained from them up to this point? Is there anything you're able to tell us right now? Or must we hold off until all 339 are enrolled and then wait for the top line results in mid-'27?
Eric, thanks, Anthony. Kevin, please take that question from Anthony.
Yes. Anthony, thanks for asking that. From a clinical standpoint, regarding those 181 patients, I don't think I can actually offer any lessons learned. What I can say is that roughly 50% of them were randomized to treatment, and that aligns with what we see in the randomized controlled trial. Not long ago, we held an in-person investigators meeting, and it drew a great crowd even though there were serious storms nationwide at the time. I was genuinely taken aback that attendance in person reached 70%, with an additional 25 to 30 people joining online. During that meeting, we could exchange best practices regarding the way we spot these patients, particular tactical targets of opportunity, approaches for engaging families, and really how to communicate with family members so that the enrollment rate is optimized; those sorts of best practices were incredibly valuable for us to exchange among all the sites, since sites differ in how much research experience they have, and it was extremely valuable to us. It created a huge amount of enthusiasm and also resulted in introductions to a range of other sites that our own investigators, PIs, referred us to. We're — once more, I believe we mentioned, and Eric said, and all of us said, that we're aiming for around year-end for our enrollment. What I can say is that we are 100% committed to that and very enthusiastic about the new sites we've identified that will appear on ClinicalTrials.gov shortly once we activate them over the coming quarter or so. Very excited about these sites and what's ahead in the next year.
Okay, Anthony, thanks. That was useful. Now, regarding perhaps the pediatric AKI area — you finished the SAVE trial. What have you discovered on the pediatric side when it comes to QUELIMMUNE? And then, about being able to bring in another 15 top-ranked children's medical centers, are you aiming for a specific number of sales reps that need to be hired this year? Or do you already have the reps you require at this point? Maybe how should we think about that metric moving forward?
All right, great. Thanks, Anthony. So Kevin, why don't you discuss a bit some of the data we've observed from a clinical standpoint, and then Tim can address the question about the 15 patients, the adoption.
Okay, Anthony, I appreciate the question. The paper itself makes the case clearly. Something that isn't fully apparent to people outside the pediatric nephrology and critical care community is that every one of these patients was basically at death's door with nothing left to try. So having more than 70% of them still alive at 90 days strikes me as a small miracle. Being able to reproduce the data that went to the FDA is a strong result. Still, for me this was unexpected, because this population was sicker. Once all 50 are reported, you'll be able to see just how ill these patients truly are, even relative to before commercialization. One interesting point: any time a life-saving technology reaches the market—I have firsthand experience, having started a CRT program 20 years ago and later ECMO—those technologies tend to be given, provided, and offered only to the sickest of the sick, as a last resort. And frequently the outcomes aren't as good as you'd expect, since you're using them on dying patients. What we are seeing, and what we have seen, is something quite miraculous. At least from my professional and personal perspective, I'm extremely pleased with this result. It demonstrates that going into the pediatric market first was worth it, and we're saving lives—that's our whole mission.
Yes. No, the results are obviously very compelling. Okay. Tim, on the sales front?
Absolutely, Anthony. To put it briefly, no — we aren't bringing on more sales staff for this initiative. Like I said, our entire focus is on the top 50 pediatric hospitals, since those give us the greatest patient volume. Our plan is to bring on 15 more. Through Q1 we already have 6 in place, and others are working their way through the pipeline. What we do anticipate doing is growing our overall — our clinical presence inside those hospitals. That means having clinical people on site so we can truly broaden our footprint at these institutions. One point — clearly, this is something we keep learning about as we go. What we're discovering is that we have strong momentum, and we need to keep building on it by bringing these educational opportunities into those institutions, so that general awareness of QUELIMMUNE grows among the institutions we partner with — so that more people and staff, patient care teams and physicians at these institutions grasp what QUELIMMUNE is, grasp which kind of patient it should be used for, how to profile that patient, and in the end, the optimal way to use it successfully. Another thing we're doing as well: we enjoy a terrific relationship with this community. One outgrowth of that is the advanced practice provider advisory board we assembled. As I noted, they'll be taking an active role at the AKI CRRT symposium later this week. And the momentum there is considerable too. So basically, we have evangelists inside the customer base who believe in this product just as strongly as we do, and we'll build on that by collaborating with them as closely as we possibly can.
Josh, thanks — and thanks to everyone who's with us on this call covering SeaStar Medical's financial results for the fourth quarter and the full year. Should you have any questions, reach out to us by email at ir@seastarmed.com, or stop by our site, www.seastarmedical.com. Thanks so much, and take care.
Appreciate it. That brings the call to an end. We're grateful you joined us. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete SeaStar Medical Holding Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to SeaStar Medical Holding Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.